GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (FRA:TA50) » Definitions » Price-to-Funds-From-Operations

Circio Holding ASA (FRA:TA50) Price-to-Funds-From-Operations : (As of May. 18, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Circio Holding ASA Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Circio Holding ASA (FRA:TA50) Business Description

Industry
Traded in Other Exchanges
Address
Vollsveien 19, Lysaker, Oslo, NOR, 1366
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.